Our mission is to prioritize targets for type 2 diabetes and its complications.

The Accelerating Medicines Partnership® (AMP®) Program Type 2 Diabetes (AMP T2D) was a precompetitive partnership among government, industry, and nonprofit organizations that harnessed the collective capabilities, scale, and resources to improve current efforts to develop new therapies for complex heterogeneous diseases, such as diabetes and diabetic complications.

One of the first three projects in the AMP portfolio, AMP T2D was managed by the FNIH from 2014-2021. Building on the success of AMP T2D, the initiative was expanded to investigate other common metabolic diseases through the AMP CMD project in May 2021.

Results + Accomplishments
  • Exceeded original goals of identifying prioritized targets for type 2 diabetes and its complications.

  • Amassed and harmonized genetic and genomic data from over 1.5 million individuals and made the data publicly accessible for querying.

  • Connected data from over 230 phenotypes and generated new genomic and target annotation data.

  • Compiled 271 unique datasets into a single resource, including data on 330 different traits relevant to type 2 diabetes.

  • Developed advanced analytical tools and methods that enabled researchers to identify target genes from noncoding genetic risk variants.

Major Unmet Medical Need

While there were a number of type 2 diabetes therapies on the market, no therapy had shown to achieve long-term reversal of the progression of hyperglycemia, or to prevent complications. Given the complex and intersecting pathways that control glucose homeostasis and energy balance, and the lack of clinical validity of existing cell and animal models, validation of drug targets for type 2 diabetes had remained challenging.

Harnessing Human Genetics

A promising approach was to take advantage of human genetics to validate drug targets. Literature had shown that by examining variants that affect type 2 diabetes and related phenotypes, researchers could unveil relevant mechanisms and pathways to validate drug targets. Therefore, the AMP T2D project explored human genetics as an approach to validate targets by exploiting experiments in nature that perturb protein functions.


Private Sector Partners
Public Sector Partners

Data Portals

T2D Knowledge Portal

The Type 2 Diabetes Knowledge Portal provides annotated and searchable genetic and genomic data from over 1.5 million individuals with type 2 diabetes.



Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients